Telesta Therapeutics will terminate its bladder cancer drug MCNA project, shutter its Montreal-based manufacturing facility and terminate another 30 percent of its workforce.
As Pfizer winds down its vaccine production at its Pearl River site, Pfizer has plans to lay off an additional 151 employees – completing a process that began in 2010 when the company opted to phase out vaccine production at the site.
Virtus Pharmaceuticals Inc. – a specialty niche pharmaceutical company and part of the Linden Capital Partners portfolio – announced it launched Prometrium (Progesterone, USP Capsules), the company’s first branded product.
Biogen Inc. said it would exercise an option to develop and commercialize an experimental genetic muscle-disorder drug after an interim analysis of late-stage data showed patients experienced statistically significant improvement.
Keryx Biopharmaceuticals Inc. withdrew its full-year 2016 forecast due to a disruption in production of its only approved drug, Auryxia.
Pfizer acquired privately held gene therapy developer Bamboo Therapeutics in a deal worth up to $645 million to boost its presence in the treatment of rare diseases.
The line between pharmaceuticals and technology is blurring as companies join forces to tackle chronic diseases using high-tech devices that combine biology, software and hardware.
Allegations were made that Celgene donated millions of dollars to charities that help patients afford high-priced cancer drugs as part of a profit-making scheme.